Keisuke Taniuchi, our CEO and Associate Professor at the Kochi University School of Medicine, will deliver a special lecture at a webinar hosted by iBody Inc. on Wednesday, April 15, 2026.

In this webinar, he will provide a detailed explanation of predicting the efficacy of adjuvant chemotherapy using a highly sensitive antibody (developed using iBody’s technology) that targets the pancreatic cancer prognostic marker “PODXL/ITGB1.” He plans to discuss efforts aimed at realizing personalized medicine utilizing next-generation antibody technology and its implementation in society.

We invite anyone interested in the leading edge of pancreatic cancer treatment and the development of new therapies and diagnostic technologies through industrial-academic collaboration to join us.

Seminar Overview

Date and Time : Wednesday, April 15, 2026, 4:00 PM – 5:00 PM (GMT +9)
Format : Zoom Webinar (Online)
Admission : Free
Topic : Preoperative Chemotherapy for Resectable Pancreatic Cancer: How to Predict Its Efficacy—Toward the Utilization of Next-Generation Monoclonal Antibody Technology
Speaker : Keisuke Taniuchi (Associate Professor, Department of Gastroenterology, Kochi University School of Medicine / CEO, Salus Science Co., Ltd.)

Time Schedule（GMT +9）

4:00 PM – 4:10 PM : Technical Presentation by iBody Co., Ltd.
4:10 PM – 4:45 PM : Special Lecture (Keisuke Taniuchi)
4:45 PM – 4:55 PM : Q&A Session

Click on the link below to check flyer (In Japanese)
https://www.ibody.co.jp/wp-content/uploads/2026/03/7eb674fedb010c8a4e1e283535dd2a4b.pdf

Click on the link below to apply forms (Redirect to an external site)
https://x.gd/bO1nG